多基因风险评分在心血管风险预测中的价值:队列研究与建模分析
该研究基于英国生物银行306,654名无心血管病史且未接受降脂治疗者,评估将多基因风险评分加入传统风险模型能否改善心血管病预测。结果显示C指数仅提高0.012,但在中危人群中定向评估可每筛查约340人预防1例额外事件,优于全人群筛查和C反应蛋白评估。
要点
- 在传统风险因素基础上加入多基因风险评分,C指数仅小幅提升0.012。
- 全人群筛查每约5750人可预防1例额外事件,中危定向筛查每约340人即可预防1例。
- 中危定向策略比传统风险预测多预防7%的心血管事件。
核心结论
- 将多基因风险评分加入传统风险因素可适度改善首发心血管病预测,若大规模应用可能带来人群健康获益。
主要发现
- 仅含传统风险预测因素的模型C指数为0.710(95%CI 0.703-0.717),加入多基因风险评分后C指数提高0.012(95%CI 0.009-0.015)。
- 加入多基因风险评分后,病例和非病例的连续净重分类改善分别约为10%和12%。
- 若对英国40-75岁全人群评估多基因风险评分并按NICE指南启动他汀治疗,约每筛查5750人可预防1例额外心血管事件。
- 仅对10年心血管风险中危(5%至<10%)人群定向评估多基因风险评分,约每筛查340人可预防1例额外心血管事件,比传统风险预测多预防7%的事件。
- 在传统风险因素基础上评估多基因风险评分的潜在获益约为评估C反应蛋白的1.5倍。
关键数值与推荐
- 多基因风险评分加入传统风险模型后C指数提高0.012(95%CI 0.009-0.015)。
- 全人群筛查策略下约每5750人预防1例额外事件;中危定向筛查策略下约每340人预防1例额外事件。
- 中危定向策略比传统风险预测多预防7%的心血管事件。
临床怎么用
- 在初级保健中,可考虑对10年心血管风险中危(5%至<10%)人群定向评估多基因风险评分以优化他汀启动决策。
- 全人群普筛多基因风险评分的绝对获益较小,需权衡筛查成本与收益。
局限性
- 研究仅纳入欧洲 ancestry 参与者,结果外推至其他种族人群需谨慎。
- 缺乏健康经济学评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polygenic risk scores (PRSs) can stratify populations into cardiovascular disease (CVD) risk groups. We aimed to quantify the potential advantage of adding information on PRSs to conventional risk factors in the primary prevention of CVD. METHODS AND FINDINGS: Using data from UK Biobank on 306,654 individuals without a history of CVD and not on lipid-lowering treatments (mean age [SD]: 56.0 [8.0] years; females: 57%; median follow-up: 8.1 years), we calculated measures of risk discrimination and reclassification upon addition of PRSs to risk factors in a conventional risk prediction model (i.e., age, sex, systolic blood pressure, smoking status, history of diabetes, and total and high-density lipoprotein cholesterol). We then modelled the implications of initiating guideline-recommended statin therapy in a primary care setting using incidence rates from 2.1 million individuals from the Clinical Practice Research Datalink. The C-index, a measure of risk discrimination, was 0.710 (95% CI 0.703-0.717) for a CVD prediction model containing conventional risk predictors alone. Addition of information on PRSs increased the C-index by 0.012 (95% CI 0.009-0.015), and resulted in continuous net reclassification improvements of about 10% and 12% in cases and non-cases, respectively. If a PRS were assessed in the entire UK primary care population aged 40-75 years, assuming that statin therapy would be initiated in accordance with the UK National Institute for Health and Care Excellence guidelines (i.e., for persons with a predicted risk of ≥10% and for those with certain other risk factors, such as diabetes, irrespective of their 10-year predicted risk), then it could help prevent 1 additional CVD event for approximately every 5,750 individuals screened. By contrast, targeted assessment only among people at intermediate (i.e., 5% to <10%) 10-year CVD risk could help prevent 1 additional CVD event for approximately every 340 individuals screened. Such a targeted strategy could help prevent 7% more CVD events than conventional risk prediction alone. Potential gains afforded by assessment of PRSs on top of conventional risk factors would be about 1.5-fold greater than those provided by assessment of C-reactive protein, a plasma biomarker included in some risk prediction guidelines. Potential limitations of this study include its restriction to European ancestry participants and a lack of health economic evaluation. CONCLUSIONS: Our results suggest that addition of PRSs to conventional risk factors can modestly enhance prediction of first-onset CVD and could translate into population health benefits if used at scale.
引用
- Sun L, Pennells L, Kaptoge S, et al. Polygenic risk scores in cardiovascular risk prediction: A cohort study and modelling analyses. PLoS Med. 2021. PMID: 33444330. doi:10.1371/journal.pmed.1003498
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。